List view / Grid view
22 January 2016 | By Victoria White
GlobalData states that the impressive growth will primarily be driven by the launch of premium-priced therapies, including anti-PD-1 and anti-CTLA-4 immunotherapies and targeted agents...
21 January 2016 | By Victoria White
The pulmonary arterial hypertension treatment market will grow from $3.45 billion in 2014 to $4.75 billion by 2024, according to research and consulting firm GlobalData...
20 January 2016 | By Victoria White
GlobalData says the expansion will be slight due to the patent expiration of all existing branded drugs in the chronic hepatitis B therapeutics space during the forecast period, and continued low diagnosis and treatment rates of the disease...
19 January 2016 | By Victoria White
GlobalData says the impressive growth in the market will be attributable to label extensions for Seattle Genetics’ Adcetris and the launch of new therapies for relapse or refractory Hodgkin’s lymphoma...
14 January 2016 | By Victoria White
The company states that the growth will be primarily down to the introduction of Telesta Therapeutics MCNA and Roche’s atezolizumab in 2016 and Bristol-Myers Squibb’s Opdivoin 2017...
13 January 2016 | By Victoria White
The RSV treatment market will rise from approximately $640 million in 2014 to over $2.3 billion by 2024, says research and consulting firm GlobalData...
13 January 2016 | By Victoria White
The glioblastoma treatment market will increase fivefold from $659 million in 2014 to $3.3 billion by 2024, according to research and consulting firm GlobalData...
13 January 2016 | By Victoria White
GlobalData states that this impressive growth will be driven primarily by the launch of Bristol-Myers Squibb’s Orencia from 2021...
8 January 2016 | By Victoria White
GlobalData states that the leading driver of this reasonably robust growth will be the anticipated launches of five biologics for the treatment of various forms of vasculitis...
5 January 2016 | By Victoria White
The minimal increase over the next decade will be largely the product of a treatment space dominated by three primary agents, namely vancomycin, Zyvox (linezolid), and Cubicin (daptomycin)...
4 January 2016 | By Victoria White
GlobalData says this rise will be driven primarily by the introduction of premium-priced therapies for advanced gastric cancer and, as a consequence, the increased uptake of therapy and lengthier treatment duration...
23 December 2015 | By Victoria White
According to GlobalData, this rise will be driven by a number of factors, including an increased use of expensive biologics, and off-label use of therapies to treat the disease...
17 December 2015 | By Victoria White
Adcetris will continue to lead the Hodgkin’s lymphoma treatment market in the US and is likely to gain swift popularity following its anticipated label extension in Europe from early 2016, according to an analyst with GlobalData...
9 December 2015 | By Victoria White
The treatment market for acute myeloid leukaemia (AML) will rapidly expand in value from $342.7 million in 2014 to reach $932.6 million by 2024, says research and consulting firm GlobalData.
1 December 2015 | By Victoria White
GlobalData says the rising number of opioid-induced constipation sufferers is largely down to overall population increase...
